Hospices Civils de Lyon

Lyon 69495

3 studies enrolling now · 21 studies all time

What they study most

ATP-Binding Cassette Subfamily C Member 6 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Cystic Fibrosis - Complete, Cystinosis, Duchenne Muscular Dystrophy, Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Epilepsy, Epilepsy in Children, Epilepsy, Tonic-Clonic, Extra-Pancreatic Neuroendocrine Tumor (epNET), Focal Seizure, Generalized Arterial Calcification of Infancy

Studies at this site

• LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve — Recruiting now
• Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors — Recruiting now
• A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) — Recruiting now
• WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment) — Recruiting now
• Natural History Study: ENPP1 Deficiency or the Early-Onset Form of ABCC6 Deficiency — Completed
• The BD Liverty™ TIPS Stent Graft Study — Running, not enrolling
• Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia — Running, not enrolling
• An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma — Running, not enrolling
• Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma — Stopped early
• Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy — Completed
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma — Running, not enrolling
• Assess Safety and Efficacy of VAD044 in HHT Patients — Running, not enrolling
• Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis — Completed
• Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) — Completed
• Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis — Completed
• Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer — Running, not enrolling
• Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer — Completed
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis — Stopped early
• Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Muscular Dystrophy — Completed
• Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis — Completed
• The Second Multicenter Hemophilia Cohort Study — Completed